

II. AMENDMENTS TO THE CLAIMS

Please cancel claims 2-5, 7-8 and 11 without prejudice to Applicants' right to file divisional applications directed to the subject matter thereof. Please amend the claims as follows:

Claim 1 (Currently Amended) The use of a combination of an inhibitor of cyclic guanosine monophosphate specific phosphodiesterase type 5 (PDE5) 5-[2-ethoxy-5(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) or a pharmaceutically acceptable salt thereof and an angiotensin II receptor antagonist selected from the group consisting of olmesartan, olmesartan medoxomil and pharmaceutically acceptable salts thereof for the palliative treatment of hypertension, including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with atherosclerosis and renovascular hypertension, congestive heart failure, angina, stroke, diabetes and impaired glucose tolerance comprising the step of administering to a patient an effective amount of said combination.

2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Currently Amended) The use according to claim 5-1, wherein the inhibitor of PDE5 the sildenafil is sildenafil citrate.
7. (Cancelled)
8. (Cancelled)
9. (Original) The use according to claim 1, wherein the medicament is for the treatment of hypertension.
10. (Currently Amended) A pharmaceutical composition comprising a-an inhibitor of cyclic guanosine monophosphate specific phosphodiesterase type 5 (PDE5)-selected from the group consisting of 5-[2-ethoxy-5(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) or a pharmaceutically acceptable salt thereof and an angiotensin II receptor antagonist selected from the group consisting of olmesartan, olmesartan medoxomil, and pharmaceutically acceptable salts thereof.
11. (Cancelled)
12. (Currently Amended) A kit for treating hypertension, the kit comprising: a) a first pharmaceutical composition comprising a-PDE5 inhibitor5-[2-ethoxy-5(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil); b) a second pharmaceutical composition comprising an angiotensin II receptor antagonist selected from the group consisting of olmesartan, olmesartan medoxomil, and pharmaceutically acceptable salts thereof; and c) a container for the compositions.
13. (Currently Amended) A method of treating hypertension in a subject comprising treating said patient separately, simultaneously, or sequentially with an effective amount of an inhibitor of PDE5 5-[2-ethoxy-5(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) and an angiotensin II receptor antagonist selected from the group consisting of olmesartan, olmesartan medoxomil, and pharmaceutically acceptable salts thereof.